Some GLP-1 medications have evidence of cardiovascular risk reduction in specific patient groups
The weight loss effects observed with GLP-1 receptor agonists led to further investigation of these medications for obesity management in patients without diabetes
Early clinical trials evaluating the efficacy of GLP-1 receptor agonists reported a slightly increased risk of acute pancreatitis with these medications versus placebo or conventional treatment
This targeted biochemical action provides a decisive therapeutic response by reinforcing the satiety signaling in the hypothalamus, enhancing insulin sensitivity, and increasing energy expenditure through glucagon-mediated hepatic signaling
Now that modern medicine has made weight loss easier than ever, its hard not to backslide and internalize the message that we should all prioritize being smaller, despite the potential risks to our mental and physical health
Drugs targeting GPCRs such as GLP-1RA, glucose-dependent insulinotropic polypeptide receptor (GIPR), and melanocortin-4 receptors (MC4R) have been approved for weight management and T2D (2, 3)
